ETST Earth Science Tech, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1538495 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.1%
TTM net income YoY33.6%
TTM EPS YoY-7.7%
Revenue 3-yr CAGR149.7%
Net income 3-yr CAGR144.1%
Margins
Gross margin70.2%
Operating margin—
Net margin11.0%
FCF margin2.2%
EBITDA margin—
Returns
ROE57.5%
ROA38.5%
ROIC (approx.)—
Asset turnover3.50x
Leverage & solvency
Liabilities / assets25.6%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.43x
Accruals ratio22.0%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $35.70M | $33.12M |
| Cost of revenue | $10.21M | $8.82M |
| Gross profit | $25.49M | $24.30M |
| SG&A expense | $3.57M | $4.15M |
| Interest expense | $16,327 | $21,189 |
| Pretax income | $3.09M | $3.37M |
| Income tax | -$511,676 | $116,776 |
| Net income | $3.63M | $3.25M |
| EPS (basic) | 0.01 | 0.01 |
| EPS (diluted) | 0.01 | 0.01 |
| Weighted avg. shares (diluted) | 293.07M | 303.52M |
| Banking | ||
| Net interest income | — | -$21,189 |
| Balance sheet | ||
| Cash & equivalents | $796,797 | $1.47M |
| Receivables | $356,054 | $129,064 |
| Inventory | $682,059 | $503,938 |
| Current assets | $3.72M | $3.11M |
| PP&E, net | $1.52M | $1.38M |
| Goodwill | $2.65M | $2.30M |
| Intangibles | $208,170 | $96,885 |
| Total assets | $8.97M | $7.07M |
| Current liabilities | $1.93M | $3.15M |
| Short-term debt | — | $179,488 |
| Total liabilities | $1.93M | $3.22M |
| Shareholders' equity | $7.01M | $3.85M |
| Shares outstanding | 291.32M | 294.30M |
| Cash flow statement | ||
| Operating cash flow | $1.94M | $4.37M |
| Capital expenditure | $756,619 | $753,165 |
| Free cash flow | $1.18M | $3.62M |
| Investing cash flow | -$1.90M | -$1.88M |
| Financing cash flow | -$712,917 | -$1.72M |
| Depreciation & amortization | $284,396 | $53,951 |
| Share buybacks | $471,410 | $1.47M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.